Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.
Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.
CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The dividend was declared by the Board of Directors on August 7, 2025. Shareholders of record as of September 15, 2025 will receive the dividend payment on October 3, 2025.
CONMED Corporation (NYSE: CNMD) reported Q2 2025 financial results with sales of $342.3 million, representing a 3.1% year-over-year increase. The company's domestic revenue grew 2.8%, while international revenue rose 3.4%. GAAP diluted EPS decreased to $0.69 from $0.96 in Q2 2024, while adjusted diluted EPS improved to $1.15 from $0.98.
The company updated its 2025 guidance, now expecting full-year revenue between $1.356-1.378 billion and adjusted diluted EPS of $4.40-$4.55. This guidance includes an estimated $0.09 EPS negative impact from recent tariff announcements in H2 2025.
Single-use products showed strong performance with 6.6% growth, while capital products declined 15.5%. The company's focus remains on strengthening supply chain operations and executing on four key growth drivers.
CONMED Corporation (NYSE: CNMD) announced that Martha Aronson will step down from its Board of Directors, effective July 7, 2025, to become President and CEO of Merit Medical. Aronson, who joined CONMED's Board in February 2016 and served as Board Chair, has been recognized for her strategic insights and contributions to the company's growth and governance.
The announcement includes statements from Pat Beyer, CONMED's President and CEO, and LaVerne Council, current Chair of the Board, both acknowledging Aronson's valuable service and leadership during her tenure since 2016.
CONMED Corporation (NYSE: CNMD) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
Investors can participate in the conference call via telephone by pre-registering to obtain dial-in details. Additionally, a webcast will be available through the "Investors" section of CONMED's website, with a replay accessible approximately one hour after the call concludes.
CONMED Corporation (NYSE: CNMD) has announced the appointment of LaVerne Council as the new Independent Chair of its Board of Directors, effective May 21, 2025. Council will succeed Martha Goldberg Aronson, who will continue to serve as a Director. The change reflects CONMED's commitment to periodic Board and Committee Chair rotations.
Council, recognized for her global operations and information technology expertise, expressed commitment to working with the Board and leadership team to execute the company's long-term strategy. The company aims to empower healthcare providers, deliver stockholder returns, create an engaging employee environment, and drive business success.
CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend payment. The company's Board of Directors has declared a dividend of $0.20 per share. The dividend was declared on May 20, 2025, and will be paid on July 3, 2025 to shareholders who are on record as of June 13, 2025.
CONMED Corporation reported Q1 2025 financial results with sales of $321.3 million, showing a 2.9% year-over-year increase. The company saw domestic revenue growth of 4.2% and international revenue growth of 1.2% (3.4% in constant currency).
Key financial metrics include:
- GAAP diluted earnings per share dropped to $0.19 from $0.63 in Q1 2024
- Adjusted diluted earnings rose to $0.95 from $0.79 year-over-year
- Gross profit margin improved to 55.3% from 55.1%
The company updated its 2025 outlook, now expecting full-year revenue between $1.350-1.378 billion and adjusted EPS of $4.45-4.60. However, recent tariff announcements could impact EPS by approximately $0.14 in H2 2025. The company noted reduced currency headwinds of 50-70 basis points, down from previous estimates of 100-120 basis points.
CONMED (NYSE: CNMD) has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the quarterly performance. Interested participants can pre-register to obtain dial-in details and passcode. The call will also be available via webcast through CONMED's investor relations website, with a replay accessible approximately one hour after the call conclusion.
CONMED (NYSE: CNMD) announced that Mark Kaye will join its Board of Directors effective February 24th, 2025. Kaye brings extensive experience in finance, accounting, risk management, strategic planning, and operational efficiencies, along with expertise in corporate governance and healthcare.
Kaye currently serves as Executive Vice President and Chief Financial Officer of Elevance Health since 2023. His previous roles include EVP and CFO at Moody's (2021-2023), SVP-CFO at Moody's (2018-2021), and leadership positions at MassMutual and Voya Financial. He has served as a Director on the Board of BCS Financial since 2024.
Both Martha Goldberg Aronson, Chair of CONMED's Board, and Patrick Beyer, President and CEO, expressed enthusiasm about Kaye's addition, highlighting how his healthcare and financial expertise will help guide CONMED's growth opportunities to benefit customers, shareholders, and employees.